Tango Therapeutics Q1 2024 GAAP EPS $(0.35) Misses $(0.31) Estimate, Sales $6.471M Miss $6.669M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tango Therapeutics (NASDAQ:TNGX) reported Q1 2024 earnings with a GAAP EPS of $(0.35), missing the $(0.31) estimate, and sales of $6.471M, below the $6.669M estimate. This represents a 9.37% increase in losses and a 12.23% increase in sales from the same period last year.
May 08, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tango Therapeutics reported a larger than expected quarterly loss and a slight miss in sales for Q1 2024, indicating a potential negative short-term impact on its stock price.
Missing both EPS and sales estimates can lead to negative investor sentiment, potentially causing a short-term decline in stock price. The increase in losses compared to the previous year further exacerbates this outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100